High Court Upholds Criminal Proceedings Against Pharmaceutical Directors in Drug Quality Case
The Jammu and Kashmir and Ladakh High Court has upheld criminal proceedings against three directors of Ahmedabad-based Corona Remedies Private Limited, emphasizing the critical link between drug quality and public health. The ruling underscores the legal responsibility of pharmaceutical companies to ensure medicines meet safety standards, as per the Drugs and Cosmetics Act, 1940.
Legal Framework and Public Health Implications
The court’s August 11 order stated that the right to life under Article 21 of the Indian Constitution includes the right to health, requiring medicines to conform to prescribed quality standards. This principle was central to the case involving Locipil tablets, which were declared “Not of Standard Quality” by a government analyst in 2016. The court emphasized that sub-standard drugs directly impact public health, making compliance with the Drugs and Cosmetics Act a constitutional obligation.
“Every person, as a consumer of medicines, is entitled to expect that drugs made available for human consumption conform to the prescribed standards of quality and are not sub-standard or otherwise unsafe,” the order stated. This aligns with precedents like the Supreme Court’s 2026 judgment in State of Kerala v M/s Panacea Biotec Ltd, which reinforced the importance of trial courts evaluating director liability on a case-by-case basis.
Directors’ Defense and Judicial Rationale
The directors argued they were not personally involved in manufacturing, citing a 2016 inspection that noted compliance with Good Manufacturing Practices. However, the court ruled that their liability hinges on evidence of negligence or consent, as outlined in Section 34 of the Drugs and Cosmetics Act. “Whether the directors were actually in charge of and responsible for the conduct of the company’s business was a question requiring evidence,” Justice Wasim Sadiq Nargal noted.
The court also highlighted the company’s response to a 2016 legal notice, where it acknowledged the findings and requested leniency. This, combined with the lack of procedural irregularities in the magistrate’s order, led to the dismissal of the petition. “The statutory safeguards… serve as an important legislative mechanism for protecting the health and life of persons who may be required to consume such drugs,” the ruling stated.
Future Trends in Pharmaceutical Regulation
Did You Know?
The 2026 Supreme Court judgment in State of Kerala v M/s Panacea Biotec Ltd specifically addressed the role of directors in ensuring compliance, a factor now central to this case.
Pro Tips for Pharmaceutical Companies
FAQ: Key Questions About the Case
What does this ruling mean for pharmaceutical directors?
The court affirmed that directors can be held liable if their negligence or failure to oversee operations leads to sub-standard drugs. However, guilt must be determined by the trial court based on evidence.
How does this impact public health policy?
The ruling reinforces the legal obligation of pharmaceutical companies to prioritize patient safety.
What role did the company’s response play?
The company’s acknowledgment of the findings and request for leniency was cited as a factor in the court’s decision to dismiss the petition, highlighting the importance of corporate accountability.
Related Articles
Understanding the Drugs and Cosmetics Act, 1940
Call to Action
Stay informed about legal developments in pharmaceutical regulation. Share your insights on how companies can better ensure drug quality, and explore our archive for deeper analyses on public health law.